Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levamisole in multiple sclerosis; with special reference to immunological parameters. A pilot study.

W Cendrowski, A Członkowska

    Acta Neurologica Scandinavica
    |April 1, 1978
    PubMed
    Summary

    Levamisole therapy did not show significant benefits for multiple sclerosis (MS) patients, with no clear impact on disease course or immune markers. Some patients experienced temporary improvements in skin hypersensitivity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Multiple sclerosis: severe exacerbation after stopping disease-modifying drugs.

    European journal of neurology·2018
    Same author

    European Academy of Neurology and European Stroke Organization consensus statement and practical guidance for pre-hospital management of stroke.

    European journal of neurology·2017
    Same author

    Intravenous thrombolysis for patients with in-hospital stroke onset: propensity-matched analysis from the Safe Implementation of Treatments in Stroke-East registry.

    European journal of neurology·2017
    Same author

    Brain iron accumulation in Wilson disease: a post mortem 7 Tesla MRI - histopathological study.

    Neuropathology and applied neurobiology·2016
    Same author

    Effect of prestroke antiplatelets use on first-ever ischaemic stroke severity and early outcome.

    International journal of clinical practice·2016
    Same author

    Factors predicting 30-day mortality in the Warsaw stroke registry.

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2015

    Area of Science:

    • Immunology
    • Neurology
    • Pharmacology

    Background:

    • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
    • Immunomodulatory therapies are explored to manage MS progression and symptoms.
    • Levamisole, an immunomodulator, has been investigated for its potential therapeutic effects.

    Purpose of the Study:

    • To evaluate the clinical efficacy of levamisole treatment in patients with multiple sclerosis.
    • To assess the impact of levamisole on immunological parameters in MS patients.
    • To determine if levamisole influences the disease course or immune response in MS.

    Main Methods:

    • A total of 35 multiple sclerosis patients received one or two courses of levamisole (100-150 mg daily).
    • Treatment durations varied from 1 month to 22 weeks.

    Related Experiment Videos

  • Clinical status was assessed using Kurtzke's disability status scale; immunological assays included lymphocyte counts, stimulation tests, E-rosette assays, and immunoglobulin levels. Skin hypersensitivity tests were also performed.

    • Main Results:

    • Immediate clinical evaluation showed no significant change in 15 patients, improvement in two, and worsening in two.
    • Follow-up after 4-14 months indicated deterioration in four additional patients, with a total of 13 relapses observed in 10 patients.
    • Levamisole did not significantly alter peripheral blood lymphocyte counts, lymphocyte stimulation, E-rosette forming cells, or serum immunoglobulin levels. However, a subset of patients showed transiently restored or potentiated skin hypersensitivity to antigens.

    Conclusions:

    • Levamisole therapy did not demonstrate a clear beneficial effect on the clinical course of multiple sclerosis in this patient group.
    • The study suggests levamisole may not be an effective treatment for MS, despite a temporary effect on skin hypersensitivity.
    • Further research is needed to definitively ascertain the role, if any, of levamisole in managing MS or its associated immune dysregulation.